Inventiva S.A. (IVA)

NASDAQ: IVA · IEX Real-Time Price · USD
3.64
+0.17 (4.90%)
Mar 31, 2023, 3:59 PM EDT - Market closed
4.9%
Market Cap 153.37M
Revenue (ttm) 18.81M
Net Income (ttm) -54.27M
Shares Out 42.13M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,588
Open 3.47
Previous Close 3.47
Day's Range 3.47 - 3.76
52-Week Range 3.40 - 12.15
Beta 1.20
Analysts Buy
Price Target 18.57 (+410.17%)
Earnings Date Mar 29, 2023

About IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. Th... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 109
Stock Exchange NASDAQ
Ticker Symbol IVA
Full Company Profile

Financial Performance

In 2022, Inventiva's revenue was $18.81 million, an increase of 121.32% compared to the previous year's $8.50 million. Losses were -$54.27 million, 9.35% more than in 2021.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IVA stock is "Buy." The 12-month stock price forecast is $18.57, which is an increase of 410.17% from the latest price.

Price Target
$18.57
(410.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F

Daix (France), Long Island City (New York, United States) , March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sma...

1 day ago - GlobeNewsWire

Inventiva reports its 2022 full-year results

Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021

2 days ago - GlobeNewsWire

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

Daix (France), Long Island City (New York, United States) , March 23 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...

1 week ago - GlobeNewsWire

Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...

1 month ago - GlobeNewsWire

Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...

1 month ago - GlobeNewsWire

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York , United States), January 30 , 2 02 3 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...

2 months ago - GlobeNewsWire

Results of the votes of the Combined Shareholders' General Meeting of January 25, 2023

Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...

2 months ago - GlobeNewsWire

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to t...

3 months ago - GlobeNewsWire

Combined General Meeting of January 25, 2023 - Availability of the preparatory documents

Daix (France), Long Island City (New York, United States), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...

3 months ago - GlobeNewsWire

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

Daix (France) , Long Island City (New York, United States), December 12 , 2 022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...

3 months ago - GlobeNewsWire

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...

4 months ago - GlobeNewsWire

Inventiva announces a new Director of the Board of Directors

Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...

4 months ago - GlobeNewsWire

Inventiva reports 2022 Third Quarter Financial Information¹

Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...

5 months ago - GlobeNewsWire

Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...

5 months ago - GlobeNewsWire

Inventiva reports its 2022 first-half financial results and provides a corporate update

Daix (France), Long Island City (New York, United States), September 22, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...

6 months ago - GlobeNewsWire

Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China

6 months ago - GlobeNewsWire

Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks

Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

7 months ago - Zacks Investment Research

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...

7 months ago - GlobeNewsWire

Inventiva Reports 2022 First-Half Financial Information¹

Daix (France), Long Island City (New York, United States), July 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develop...

8 months ago - GlobeNewsWire

Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

Daix (France), Long Island City (New York, United States), July 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

9 months ago - GlobeNewsWire

Update on Inventiva's cash position and on the finance documentation with the European Investment Bank

Daix (France), Long Island City (New York, United States), July 4, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...

9 months ago - GlobeNewsWire

Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

Daix (France), Long Island City (New York, United States), June 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sma...

10 months ago - GlobeNewsWire

Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher

Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.

10 months ago - Zacks Investment Research

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

Daix (France), Long Island City (New York, United States), June 9, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

10 months ago - GlobeNewsWire

Inventiva joins the Euronext Tech Leaders segment

Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...

10 months ago - GlobeNewsWire